secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001104659-23-072308
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance enters $450M ATM equity offering with Jefferies, replaces prior program
-------------------------------------------------------------------------------

- Company entered new Open Market Sale Agreement with Jefferies for up to $450M in at-the-market common stock sales.
- Jefferies will receive commission of up to 3% of gross proceeds under the new program.
- Prior ATM agreement dated November 18, 2022 was terminated concurrently.
- Sales may be made through various methods including ordinary brokers' transactions on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923072308/0001104659-23-072308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923072308/tm2318914d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-072308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer